Participating Faculty

Best Practices for Natalizumab Utilization in the Treatment of Multiple Sclerosis

This supplement to The American Journal of Managed Care reviews the clinical and economic burden of multiple sclerosis and summarizes the efficacy and safety of natalizumab. The impact of natalizumab on clinical and economic outcomes is discussed. The role of natalizumab in clinical practice is outlined, with emphasis on selection of appropriate patients for treatment.

Faculty

David W. Brandes, MS, MD, FAAN

Hope Neurology

Knoxville, Tennessee

Assistant Clinical Professor, Neurology

University of California, Los Angeles

Los Angeles, California

Patricia K. Coyle, MD

Professor and Acting Chair

Department of Neurology

Stony Brook University Medical Center and Stony Brook MS Comprehensive Care Center

Stony Brook, New York

John Foley, MD

Director

Rocky Mountain Multiple Sclerosis Clinic

Rocky Mountain Neurological Associates

Salt Lake City, Utah

Michael W. Pill, PharmD

President

Gemini Healthcare, LLC

Westbrook, Connecticut

Fadia T. Shaya, PhD, MPH

Associate Professor

University of Maryland School of Pharmacy

Baltimore, Maryland

Faculty Disclosures

These faculty report relationships with the following organizations:

David W. Brandes, MS, MD, FAAN

Consultant/advisory board/honoraria/lectureship:

Bayer

Biogen Idec

EMD Serono

Teva

Patricia K. Coyle, MD

Board membership:

Bayer

Novartis

Consultant/advisory board:

Acorda

Bayer

Biogen Idec

EMD Serono

Pfizer

sanofi-aventis

Teva

Grants:

Novartis

sanofi-aventis

Honoraria/lectureship:

Bayer

Biogen Idec

EMD Serono

Novartis

Pfizer

sanofi-aventis

Teva

John Foley, MD

Advisory board:

Biogen Idec

Honoraria/lectureship:

Biogen Idec

Genentech

Teva

Michael W. Pill, PharmD, and Fadia T. Shaya, PhD, MPH, have nothing to disclose.

This supplement was supported by Biogen Idec Inc.

The contents of this supplement may include information regarding the use of products that may be inconsistent

with or outside the approved labeling for these products in the United States. Physicians should note that the

use of these products outside current approved labeling is considered experimental and are advised to consult

prescribing information for these products.

Download PDF: Participating Faculty